VR Adviser’s Spero Therapeutics SPRO Stock Holding History

VR Adviser’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-474,015	Closed	-$3.83M	–	22
2020 Q1	$3.83M	Buy	+474,015	New	+$4.18M	1.04%	15

Other funds holding SPRO

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VR Adviser's SPRO Position: Q2 2020 in Review

VR Adviser sold out of Spero Therapeutics (SPRO) in Q2 2020, closing a stake of 474,015 shares — an estimated $3.83M sold.

VR Adviser first reported a position in SPRO in Q1 2020 and held it in 1 quarter. The position peaked at $3.83M in Q1 2020. 80 funds tracked by Wall St. Rank hold SPRO as of Q2 2020.

VR Adviser reported no remaining Spero Therapeutics position as of Q2 2020 after selling out during the quarter.
VR Adviser sold 474,015 Spero Therapeutics shares in Q2 2020, an estimated $3.83M.
VR Adviser first reported a position in Spero Therapeutics in Q1 2020 and held it in 1 quarter.
VR Adviser's Spero Therapeutics position peaked at $3.83M in Q1 2020.
80 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2020.

Based on VR Adviser's 13F filing for Q2 2020, filed 14 Aug 2020.